Breast Cancer Trial, Recruiting NCT05263570 Sponsor: Shengjing Hospital Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT05263570
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People diagnosed with a specific type of breast cancer known as HR-positive, HER2-negative (this refers to the hormone and protein markers found on the cancer cells)
  • Women with Stage II or Stage III breast cancer (meaning the cancer has not spread to distant parts of the body) who are being admitted for breast cancer treatment for the first time
  • People whose treating doctor has determined they will receive one of the standard chemotherapy treatment combinations used in this trial
  • People whose full medical history is available and on record
  • People with a general health and functioning score of 70 or above on a standard medical scale, meaning they are able to carry out normal daily activities with some difficulty at most (confirm with trial site)

Who may not be able to join:

  • Women who have already received any type of cancer treatment, including chemotherapy, radiation therapy, targeted therapy, or hormone therapy
  • Women who are pregnant or currently breastfeeding
  • People diagnosed with cancer in both breasts at once, inflammatory breast cancer, or occult breast cancer (a rare form where the primary tumour is difficult to detect)
  • People diagnosed with Stage IV breast cancer, meaning the cancer has spread to distant parts of the body

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Caigang Liu, PHD, Shengjing Hospital

Phone: +8618940256668

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shengjing Hospital
Registry
ClinicalTrials.gov
Start date
1 August 2022
Est. completion
31 December 2023

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Total pathological complete response (tpCR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov